4-(hydroxymethyl)-3-methylfuroxan | 183537-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(hydroxymethyl)-3-methylfuroxan
• 英文别名: (4-methyl-5-oxido-1,2,5-oxadiazol-5-ium-3-yl)methanol
• CAS: 183537-57-7
• 化学式: C₄H₆N₂O₃
• 分子量: 130.103
• InChiKey: ZWKIHZPJVCZRHC-UHFFFAOYSA-N

物化性质

• 沸点：
  294.4±32.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)-3-methylfuroxan 在 氯化亚砜 作用下， 生成 3-methyl-4-chloromethyl-furoxane
  参考文献：
  名称：

  新型杂化查尔酮衍生物作为血管舒张剂的合成及生物学评价

  摘要：

  为了进一步改善查尔酮的血管舒张活性，基于分子杂交策略设计合成了九种杂化查尔酮衍生物，它们与一氧化氮（NO）供体或1,4-二氢吡啶基（1,4-DHP）部分共轭。他们的血管舒张活性被评估在主动脉环与苯肾上腺素（PE）预收缩的内皮细胞。所有这些化合物均表现出优选的血管舒张活性，比其母体化合物更有效。化合物8c和15c是最有效的化合物，将成为开发新型血管松弛剂的有前途的结构模板。

  DOI：

  10.1016/j.ejmech.2010.05.054
• 作为产物：
  描述：

  4-formyl-3-methylfuroxan 在 sodium cyanoborohydride 作用下， 以 四氢呋喃 为溶剂， 以50%的产率得到4-(hydroxymethyl)-3-methylfuroxan
  参考文献：
  名称：

  设计为新型杀菌剂的呋喃喃衍生物的合成及抗真菌活性。

  摘要：

  设计并合成了呋喃喃衍生物3-11作为潜在的杀菌剂。通过原位由N-羟基亚氨酰氯2生成的相应的腈氧化物的二聚作用，制备对称取代的呋喃喃衍生物3a-j。关键中间体醛4的进一步官能团修饰生成了呋喃喃衍生物5-11。在250 ppm的广谱植物真菌中观察到了呋喃喃衍生物3-11的杀真菌活性。

  DOI：

  10.1271/bbb.62.1693

文献信息

• 苯并咪唑衍生物及其制备方法和医药用途
  申请人：武汉朗来科技发展有限公司

  公开号：CN105237527B

  公开（公告）日：2018-03-06

  本发明属于药物化学技术领域，具体公开了一类苯并咪唑衍生物及其制备方法和医药用途。苯并咪唑衍类生物包括川芎嗪和NO供体类衍生物，该类化合物在体内迅速释放出川芎嗪或NO，从而与阿齐沙坦发生有效的协同作用，增强抗高血压疗效，减少不良反应，对患者肝肾具有较理想的保护作用，填补了现有技术中的空白。
• Benzimidazole Derivatives and Preparation Process and Pharmaceutical Uses Thereof
  申请人：WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD

  公开号：US20170022188A1

  公开（公告）日：2017-01-26

  The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include Ligustrazine and NO donor derivatives. The kind of the compounds can rapidly release Ligustrazine or No in vivo, so that they can produce effective synergetic effects with Azilsartan, to enhance the anti-hypertension effect, and reduce adverse effects, and the released Ligustrazine can produce ideal protection to patients' livers and kidneys, thereby filling blanks in the prior art

  这项发明属于药物化学技术领域，特别涉及苯并咪唑衍生物及其制备工艺和药用用途。苯并咪唑衍生物包括川芎素和NO供体衍生物。这些化合物可以在体内快速释放川芎素或NO，从而能够与阿利沙坦产生有效的协同作用，增强抗高血压效果，减少不良反应，释放的川芎素可以对患者的肝脏和肾脏产生理想的保护作用，从而填补了先前技术领域的空白。
• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20080287407A1

  公开（公告）日：2008-11-20

  The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

  该发明描述了新颖的硝化和/或亚硝化丙酮酸盐及其药用可接受盐，以及包含至少一种硝化和/或亚硝化丙酮酸化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种丙酮酸化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种丙酮酸化合物的新型试剂盒，该丙酮酸化合物可选地硝化和/或亚硝化，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了治疗由氧化应激、糖尿病、缺血后再灌注损伤、组织、器官、器官部分和/或肢体保护引起的疾病的方法。
• Nitric Oxide Donor β₂-Agonists:  Furoxan Derivatives Containing the Fenoterol Moiety and Related Furazans
  作者：M. Federica Buonsanti、Massimo Bertinaria、Antonella Di Stilo、Clara Cena、Roberta Fruttero、Alberto Gasco

  DOI：10.1021/jm0704595

  日期：2007.10.1

  has been joined with furoxan NO-donor moieties to give new NO-donor beta2-agonists. The furazan analogues, devoid of the property to release NO, were also synthesized for comparison. All the compounds retained beta2-agonistic activity at micromolar or submicromolar concentration when tested on guinea pig tracheal rings precontracted with carbachol. Among the furoxan derivatives, the NO contribution

  非诺特罗（一种用于治疗的β2肾上腺素受体激动剂）的结构已与呋喃喃的NO供体基团结合在一起，得到了新的NO供体β2受体激动剂。还合成了不具有释放NO的性质的呋喃赞类似物以进行比较。当在与卡巴胆碱预收缩的豚鼠气管环上进行测试时，所有化合物在微摩尔或亚微摩尔浓度下均保持β2激动活性。在呋喃喃衍生物中，在微摩尔浓度的产物15b中，NO对气管舒张的作用是明显的。所有这些新的NO供体杂种都能够扩张与去氧肾上腺素预收缩的大鼠主动脉条。呋喃喃和呋喃山衍生物均显示出比非诺特罗更大的抗氧化活性。